A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)
Public ClinicalTrials.gov record NCT07216703. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Randomized, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab With or Without Bevacizumab Compared With Standard of Care as Firstline Maintenance Treatment for Participants With Persistent, Recurrent, or Newly Diagnosed Metastatic Cervical Cancer With PD-L1 CPS Greater Than or Equal to 1 (TroFuse-036/GOG-3123/ENGOT-cx22)
Study identification
- NCT ID
- NCT07216703
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Enrollment
- 1,023 participants
Conditions and interventions
Conditions
Interventions
- Bevacizumab Biological
- Carboplatin Drug
- Cisplatin Drug
- Paclitaxel Drug
- Pembrolizumab Biological
- Rescue Medications Drug
- Sacituzumab Tirumotecan Biological
Biological · Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 18, 2026
- Primary completion
- Oct 28, 2031
- Completion
- Oct 28, 2031
- Last update posted
- May 7, 2026
2026 – 2031
United States locations
- U.S. sites
- 12
- U.S. states
- 9
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Mount Sinai Comprehensive Cancer Center ( Site 6000) | Miami Beach | Florida | 33140 | Recruiting |
| Florida Cancer Specialists - East ( Site 7000) | West Palm Beach | Florida | 33401 | Recruiting |
| TRIALS 365 ( Site 6008) | Shreveport | Louisiana | 71103 | Recruiting |
| Minnesota Oncology Hematology, PA ( Site 8003) | Minneapolis | Minnesota | 55404 | Recruiting |
| Women's Cancer Center of Nevada ( Site 6011) | Las Vegas | Nevada | 89106 | Recruiting |
| Laura and Isaac Perlmutter Cancer Center at NYU Langone ( Site 6009) | New York | New York | 10016 | Recruiting |
| Oncology Associates of Oregon, P.C.(Willamette Valley Cancer Institute) (WVCI) ( Site 8007) | Eugene | Oregon | 97401 | Recruiting |
| University of Tennessee Medical Center ( Site 6012) | Knoxville | Tennessee | 37920 | Recruiting |
| Texas Oncology - DFW ( Site 8005) | Fort Worth | Texas | 76104 | Recruiting |
| Texas Oncology-The Woodlands ( Site 8000) | The Woodlands | Texas | 77380 | Recruiting |
| Texas Oncology - Northeast Texas ( Site 8002) | Tyler | Texas | 75702 | Recruiting |
| University of Virginia Cancer Center ( Site 6014) | Charlottesville | Virginia | 22908 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 79 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07216703, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 7, 2026 · Synced May 9, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07216703 live on ClinicalTrials.gov.